Contents

Current Drug Targets, Volume 3 - Number 6

Preface

, 3(6): i

George J. Christ


DOI: 10.2174/1389450023347407




Gap Junction Synthesis and Degradation as Therapeutic Targets

, 3(6): 409 - 416

Eric C. Beyer and Viviana M. Berthoud


DOI: 10.2174/1389450023347245




Are Gap Junction Channels a Therapeutic Target and if so What Properties are Best Exploited?

, 3(6): 417 - 425

Peter R. Brink


DOI: 10.2174/1389450023347326




The Physiology, Pathophysiology and Therapeutic Potential of Gap Junctions in Smooth Muscle

, 3(6): 427 - 440

G. Lagaud, K.P. Davies, K. Venkateswarlu and G. J. Christ


DOI: 10.2174/1389450023347399




Mutagenic Approaches to Modifying Gap Junction Phenotype

, 3(6): 441 - 453

S. N. Zucker and B. J. Nicholson


DOI: 10.2174/1389450023347218




Prospects for Rational Development of Pharmacological Gap Junction Channel Blockers

, 3(6): 455 - 464

David C. Spray, Renato Rozental and Miduturu Srinivas


DOI: 10.2174/1389450023347353




Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy

, 3(6): 465 - 482

J.E. Trosko and R.J. Ruch


DOI: 10.2174/1389450023347371




Connexin-GFPs Shed Light on Regulation of Cell-Cell Communication by Gap Junctions

, 3(6): 483 - 499

Vytas K. Verselis and Feliksas F. Bukauskas


DOI: 10.2174/1389450023347272




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science